stockportfolio.pro
Immunocore Holdings plc (IMCR)
Healthcare · Biotechnology · NasdaqGS
Immunocore Holdings plc revenue & earnings — last 5 fiscal years
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $36.48M | $174.36M | $249.43M | $310.20M | $400.02M |
| Gross profit | — | $173.27M | $248.39M | $307.47M | $394.93M |
| Net income | $-180.03M | $-52.54M | $-55.29M | $-51.09M | $-35.51M |
| Net margin | -493.4% | -30.1% | -22.2% | -16.5% | -8.9% |
Source: Immunocore Holdings plc SEC filings (10-K).
Explore 5 years of Immunocore Holdings plc financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track IMCR in your portfolio →
Immunocore Holdings plc financial history by metric
About Immunocore Holdings plc
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Immunocore Holdings plc — frequently asked questions
What is Immunocore Holdings plc's revenue?
Immunocore Holdings plc (IMCR) reported revenue of $400.02M for fiscal year 2025, up 29.0% from the prior year, according to its SEC filings.
Is Immunocore Holdings plc profitable?
No — IMCR reported a net loss of $-35.51M in fiscal 2025.
What is IMCR's P/E ratio?
Immunocore Holdings plc trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Immunocore Holdings plc growing?
IMCR's revenue grew at roughly 82.0% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Immunocore Holdings plc have?
As of fiscal year 2025, IMCR carried roughly $393.13M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Immunocore Holdings plc's gross margin?
IMCR's gross margin was 98.7% in fiscal 2025 — gross profit of $394.93M on revenue of $400.02M.
What is Immunocore Holdings plc's market cap?
Immunocore Holdings plc (IMCR) has a market capitalization of about $1.44B, based on the latest data in our nightly-refreshed cache.
When does Immunocore Holdings plc's fiscal year end?
IMCR's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Immunocore Holdings plc's official SEC filings (10-K and 10-Q), covering 5 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.